Status:
TERMINATED
Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
This study is to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of multiple ascending doses of AZD0328 in patients with schizophrenia
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia according to the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition)
- Low level of Extra-pyramidal symptoms
- No clinically significant findings on physical examination
Exclusion
- Diagnosis of schizoaffective or schizophreniform disorders
- Any significant psychiatric or neurological disease other than schizophrenia
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00669903
Start Date
April 1 2008
End Date
November 1 2008
Last Update
August 6 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Center
Garden Grove, California, United States
2
Research Center
Glendale, California, United States